Based on 60 years of cancer diagnostic expertise, 30 years of molecular pathology and 10 years of next generation sequencing, OncoDNA’s services for clinical trials are: Clinical Testing, Precision Enrolment and Knowledge Driven Medicine.
Reducing delays and cost in patient recruitment
Accessing a pool of patients fully characterised to serve your R&D activities and clinical trials
Building your CDx strategy using our technical regulatory expertise
Offering NGS and molecular pahtology as stand-alone or integrated assay
Two exclusive solutions to improve the characterisation of clinical trial’s patients and to ease treatment monitoring.
Meet your recruitment targets & deadlines by granting treatment access to fully characterised patients.
OncoKDM: Make it your data interpretation pipeline, from patient to trials meta-analyses.
We support biopharma companies to access the market and bring better outcomes for patients
by providing comprehensive biomarker testing to support clinical and treatment decision (CDS)
by gathering physician practices and patient outcomes efficiently (RWE)
by facilitating real-time monitoring of genomic and clinical response to treatment (resistance, progression, relapse and residual cancer burden)
by measuring real impact of a treatment on improved outcomes and quality of care (Clinical Outcome Assessment - COA)
by improving disease, therapies and market awareness
"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"
The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)
Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]